Swedish Orphan Biovitrum has agreed to an additional Kineret® drug campaign with Amgen

Goals, mission and background Business Strategy CEO'S STATEMENT History 10 year overview Press releases News Financial Reports Calendar Image gallery Presentations Corporate Governance

Home / ...

3/12/2010

Stockholm, Sweden - March 12, 2009 - Swedish Orphan Biovitrum (STO: BVT) today announced an agreement with Amgen to run an additional Kineret® bulk drug campaign. In addition, Swedish Orphan Biovitrum will pay to buy-out previously agreed future sales milestones for Kineret® and Kepivance®.

Please read the whole press release here.